Results from AMEERA-5 published in Journal of Clinical Oncology

Paolo Tarantino shared a post on X:

“Results from AMEERA-5 published in Journal of Clinical Oncology. Among 1068 pts with ER+/HER2- MBC randomized to 1L amcenestrant/palbo vs AI/palbo, no improvement in PFS was seen, with the HR favoring the AI. Still unclear if 1L SERD for unselected pts will improve outcomes. ”

Read further.
Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.